AlbertCLockhartMD

Oncology • Charleston, SC

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University in St. Louis School of Medicine

Join to view full profile

Dr. Lockhart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lockhart's full profile

Already have an account?

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Fax+1 305-243-9161

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
University of Texas Southwestern Medical SchoolClass of 1993

Certifications & Licensure

SC State Medical License 2021 - 2025
FL State Medical License 2017 - 2023
MO State Medical License 2008 - 2018
TN State Medical License 2001 - 2010
NC State Medical License 1999 - 2003
TX State Medical License 1995 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting

Publications & Presentations

PubMed

Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab.
Jared Weiss, Douglas Laux, David Bajor, Albert C Lockhart, John Hamm
Future Science OA. 2024-12-01
37 citations
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C Lockhart
Clinical Cancer Research. 2022-12-15
7 citations
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg
Future Oncology. 2022-07-19

Press Mentions

US Patent for Cannabis-Derived Drug to Treat Eye DiseasesMay 22nd, 2019
Lowe’s Flavocure Secures US Patent for Ganja Eye DrugMay 17th, 2019
$10.4 Million Awarded for Pancreatic Cancer ResearchAugust 15th, 2016

Grant Support

Pharmacogenomically Selected Treatment For Gastric And Gastroesophageal JunctionNational Cancer Institute2008
Genetic Polymorphisms Affecting Chemotherapy DispositionNational Cancer Institute2008
Genetic Polymorphisms Affecting Chemotherapy DispositionNational Cancer Institute2004–2008
Pharmacogenomically Selected Treatment For Gastric And Gastroesophageal JunctionNational Cancer Institute2007
Response To Paclitaxel Related To Genitic Variatins In MDR1National Center For Research Resources2006
Correlation On The Pharmacokinetics And Toxicity Of CPT-11 With FunctionallyNational Center For Research Resources2005–2006